JO3459B1 - تركيبات صيدلانية لعلاج مرض الزهايمر - Google Patents
تركيبات صيدلانية لعلاج مرض الزهايمرInfo
- Publication number
- JO3459B1 JO3459B1 JOP/2013/0248A JOP20130248A JO3459B1 JO 3459 B1 JO3459 B1 JO 3459B1 JO P20130248 A JOP20130248 A JO P20130248A JO 3459 B1 JO3459 B1 JO 3459B1
- Authority
- JO
- Jordan
- Prior art keywords
- alzheimer
- disease
- treatment
- pharmaceutical formulations
- span
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698664P | 2012-09-09 | 2012-09-09 | |
| US201361782084P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3459B1 true JO3459B1 (ar) | 2020-07-05 |
Family
ID=49118521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0248A JO3459B1 (ar) | 2012-09-09 | 2013-08-21 | تركيبات صيدلانية لعلاج مرض الزهايمر |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9375418B2 (https=) |
| EP (1) | EP2892563B1 (https=) |
| JP (2) | JP6693744B2 (https=) |
| KR (2) | KR20150065680A (https=) |
| CN (1) | CN104619344A (https=) |
| AP (1) | AP2015008306A0 (https=) |
| AU (1) | AU2013311573B2 (https=) |
| BR (1) | BR112015005117B1 (https=) |
| CA (1) | CA2883751C (https=) |
| CL (1) | CL2015000578A1 (https=) |
| CY (1) | CY1121062T1 (https=) |
| DK (1) | DK2892563T3 (https=) |
| EA (1) | EA030448B1 (https=) |
| ES (1) | ES2703630T3 (https=) |
| GE (1) | GEP201706776B (https=) |
| HR (1) | HRP20182069T1 (https=) |
| IL (1) | IL237369B (https=) |
| JO (1) | JO3459B1 (https=) |
| LT (1) | LT2892563T (https=) |
| MX (1) | MX368305B (https=) |
| MY (1) | MY182539A (https=) |
| NI (1) | NI201500031A (https=) |
| NZ (1) | NZ630589A (https=) |
| PL (1) | PL2892563T3 (https=) |
| PT (1) | PT2892563T (https=) |
| RS (1) | RS58104B1 (https=) |
| RU (1) | RU2675786C2 (https=) |
| SG (1) | SG11201501774QA (https=) |
| SI (1) | SI2892563T1 (https=) |
| SM (1) | SMT201800678T1 (https=) |
| TN (1) | TN2015000076A1 (https=) |
| TW (1) | TWI632909B (https=) |
| WO (1) | WO2014037532A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| ES2654288T3 (es) | 2013-03-14 | 2018-02-13 | Janssen Pharmaceutica, N.V. | Moduladores de P2X7 |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| JO3639B1 (ar) | 2014-07-04 | 2020-08-27 | H Lundbeck As | صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| CA2960968A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| WO2016039983A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
| CN105175307A (zh) * | 2014-11-18 | 2015-12-23 | 苏州晶云药物科技有限公司 | Lu AE58054的盐酸盐晶型A及其制备方法和用途 |
| CN107847499A (zh) * | 2015-05-07 | 2018-03-27 | 阿速万科学有限责任公司 | 治疗神经退行性疾病的方法 |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CN118806909A (zh) * | 2016-04-26 | 2024-10-22 | H.隆德贝克有限公司 | 乙酰胆碱酯酶抑制剂和艾达鲁吡啶用于减少帕金森氏病患者跌倒的用途 |
| US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
| JP6606299B2 (ja) | 2016-05-18 | 2019-11-13 | スヴェン・ライフ・サイエンシズ・リミテッド | 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ |
| CN106309436A (zh) * | 2016-07-25 | 2017-01-11 | 宁波大学 | 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途 |
| CN107118146B (zh) * | 2017-04-13 | 2019-09-03 | 宁波大学 | 一种6-溴色胺衍生物及其制备方法和用途 |
| MX385719B (es) * | 2017-05-24 | 2025-03-18 | H Lundbeck As | Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4 |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| EP3856178B1 (en) | 2018-09-28 | 2026-03-11 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| MX2022003819A (es) | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| EP3960174B1 (en) | 2020-08-28 | 2024-10-30 | Westfälische Wilhelms-Universität Münster | Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use |
| CN121013715A (zh) * | 2024-03-22 | 2025-11-25 | 艾瑞克·奎因 | 镁和利多卡因组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3597149A (en) | 1969-04-29 | 1971-08-03 | Showa Denko Kk | Inhibition of gas-fume fading of dyed cellulose acetate material |
| FR2181559A1 (en) | 1972-04-28 | 1973-12-07 | Aec Chimie Organique Bio | N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity |
| JPS5764632A (en) | 1980-10-09 | 1982-04-19 | Mitsui Toatsu Chem Inc | Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide |
| US5202336A (en) | 1986-09-24 | 1993-04-13 | Bayer Aktiengesellschaft | Antiflammatory quinolin methoxy phenylsulphonamides |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
| CA2147991A1 (en) | 1993-09-01 | 1995-03-09 | Richard A. Glennon | Tryptamine analogs with 5-ht1d selectivity |
| US5504101A (en) | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
| DK1032559T3 (da) | 1997-09-29 | 2007-02-26 | Aventis Pharma Inc | Aminoalkylphenolderivater til behandling af depression og hukommelsessvigt |
| GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| DK1149078T3 (da) | 1998-12-11 | 2006-07-10 | Univ Virginia Commonwealth | Selektive 5-HT6-receptorligander |
| IL144289A0 (en) | 1999-01-13 | 2002-05-23 | Millennium Pharm Inc | Functionalized heterocycles as chemokine receptor modulators |
| US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| DE60222396T2 (de) * | 2001-03-29 | 2008-05-15 | Eli Lilly And Co., Indianapolis | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste |
| RU2252936C2 (ru) * | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты) |
| PE20071143A1 (es) | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CA2658959A1 (en) | 2006-06-23 | 2007-12-27 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| CA2768668A1 (en) * | 2009-07-23 | 2011-01-27 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
| TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
| JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2013
- 2013-08-21 JO JOP/2013/0248A patent/JO3459B1/ar active
- 2013-09-06 HR HRP20182069TT patent/HRP20182069T1/hr unknown
- 2013-09-06 PL PL13759195T patent/PL2892563T3/pl unknown
- 2013-09-06 AU AU2013311573A patent/AU2013311573B2/en active Active
- 2013-09-06 KR KR1020157007345A patent/KR20150065680A/ko not_active Ceased
- 2013-09-06 WO PCT/EP2013/068516 patent/WO2014037532A1/en not_active Ceased
- 2013-09-06 ES ES13759195T patent/ES2703630T3/es active Active
- 2013-09-06 SG SG11201501774QA patent/SG11201501774QA/en unknown
- 2013-09-06 SM SM20180678T patent/SMT201800678T1/it unknown
- 2013-09-06 EA EA201590353A patent/EA030448B1/ru not_active IP Right Cessation
- 2013-09-06 AP AP2015008306A patent/AP2015008306A0/xx unknown
- 2013-09-06 BR BR112015005117-0A patent/BR112015005117B1/pt active IP Right Grant
- 2013-09-06 GE GEAP201313752A patent/GEP201706776B/en unknown
- 2013-09-06 SI SI201331303T patent/SI2892563T1/sl unknown
- 2013-09-06 EP EP13759195.4A patent/EP2892563B1/en active Active
- 2013-09-06 PT PT13759195T patent/PT2892563T/pt unknown
- 2013-09-06 CN CN201380046768.6A patent/CN104619344A/zh active Pending
- 2013-09-06 NZ NZ630589A patent/NZ630589A/en unknown
- 2013-09-06 RU RU2015107877A patent/RU2675786C2/ru active
- 2013-09-06 MX MX2015002879A patent/MX368305B/es active IP Right Grant
- 2013-09-06 MY MYPI2015000575A patent/MY182539A/en unknown
- 2013-09-06 TW TW102132182A patent/TWI632909B/zh active
- 2013-09-06 LT LTEP13759195.4T patent/LT2892563T/lt unknown
- 2013-09-06 KR KR1020207034028A patent/KR102342127B1/ko active Active
- 2013-09-06 JP JP2015530420A patent/JP6693744B2/ja active Active
- 2013-09-06 RS RS20181571A patent/RS58104B1/sr unknown
- 2013-09-06 CA CA2883751A patent/CA2883751C/en active Active
- 2013-09-06 DK DK13759195.4T patent/DK2892563T3/en active
- 2013-09-09 US US14/021,033 patent/US9375418B2/en active Active
-
2015
- 2015-02-23 IL IL237369A patent/IL237369B/en active IP Right Grant
- 2015-03-02 TN TNP2015000076A patent/TN2015000076A1/fr unknown
- 2015-03-06 NI NI201500031A patent/NI201500031A/es unknown
- 2015-03-06 CL CL2015000578A patent/CL2015000578A1/es unknown
-
2016
- 2016-03-30 US US15/084,712 patent/US9687473B2/en active Active
- 2016-06-28 US US15/194,947 patent/US9789085B2/en active Active
-
2017
- 2017-09-06 US US15/696,880 patent/US10660878B2/en active Active
-
2018
- 2018-12-06 JP JP2018228631A patent/JP2019059760A/ja active Pending
- 2018-12-21 CY CY181101390T patent/CY1121062T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3459B1 (ar) | تركيبات صيدلانية لعلاج مرض الزهايمر | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
| EA201590975A1 (ru) | Ингибиторы prmt5 и их применение | |
| PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201690283A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA201791030A1 (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EA201590074A1 (ru) | Производное бензодиоксола, способ его получения и его применение | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| NZ727251A (en) | Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s | |
| MA37957A1 (fr) | Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées | |
| UA123899U (uk) | Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази |